Answers are grounded in this paper and cite their sources.
Abstract The association of graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects after allogeneic stem-cell transplantation (SCT) is well-established but was not confirmed in modern era and following post-transplant cyclophosphamide (PTCy). We assessed GVHD/ GVL association in AML patients following HLA-matched SCT with standard calcineurin-based (n = 12,653) or PTCy-based (n = 508) GVHD prophylaxis. Following standard prophylaxis, the rates of acute GVHD grade II-IV and III-IV, chronic GVHD and extensive chronic GVHD were 23.8%, 7.5%, 37.0% and 16.3%, respectively. Acute GVHD grade II and III-IV were associated with lower relapse [hazard-ratio (HR) 0.85, P = 0.002; HR 0.76, P = 0.003, respectively)], higher non-relapse mortality (NRM) (HR 1.5, P < 0.001; HR 6.21, P < 0.001) and lower overall-survival (OS) (HR 1.49, P < 0.001; HR 6.1, P < 0.001). Extensive chronic GVHD was associated with lower relapse (HR 0.69, P < 0.001), higher NRM (HR 2.83, P < 0.001) and lower OS (HR 2.74, P < 0.001). Following PTCy, GVHD rates were 22.8%, 6.2%, 35.5% and 17.7%, respectively. Acute GVHD grade II-IV was not associated with relapse (HR 1.37, P = 0.15) but predicted higher NRM (HR 3.34, P < 0.001) and lower OS (HR 1.92, P = 0.001). Chronic GVHD was not prognostic for these outcomes. In conclusion, GVHD and GVL are strongly associated in contemporary SCT. However, following PTCy, GVHD is not associated with reduced relapse.
No takes yet. Share an insight, caveat, or question.
Shimoni et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: